Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea
The objective of the study is to assess interim results and safety of BDQ for the treatment of MDR-TB from July 2015 to 2017
Abstract
Bedaquiline (BDQ) was introduced in the multidrug-resistant tuberculosis (MDR-TB) programme in Daruin remote Papua New Guinea in 2015, along with a core package of active drug-safety monitoring (aDSM). The objective of the study is to assess interim results and safety of BDQ for the treatment of MDR-TB from 1 July 2015 to 31 December 2017
This research was supported by the UK Department for International Development’s Operational Research Capacity Building Programme led by the International Union Against TB and Lung Disease (The Union)
Citation
Taune M, Ustero P, Hiashiri S, Huang K, Aia P, Morris L, Main S, Chan G, du Cros P, Majumdar SS. Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua New Guinea. Public Health Action. 2019;9(1):S73–9.